Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA.
Yamada S, Uchida Y, Kouyama JI, Naiki K, Tsuji S, Uemura H, Sugawara K, Nakayama N, Imai Y, Tomiya T, Mizuno S, Mochida S. Yamada S, et al. Among authors: uemura h. Hepatol Res. 2024 Oct;54(10):877-887. doi: 10.1111/hepr.14036. Epub 2024 Mar 22. Hepatol Res. 2024. PMID: 38517681
Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy.
Uemura H, Uchida Y, Kouyama JI, Naiki K, Yamaba S, Fuchigami A, Saito Y, Shiokawa K, Fujii Y, Uchiya H, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Uemura H, et al. Hepatol Res. 2018 Mar;48(4):233-243. doi: 10.1111/hepr.12980. Epub 2017 Oct 20. Hepatol Res. 2018. PMID: 28884930
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Uchida Y, Nakao M, Yamada S, Tsuji S, Uemura H, Kouyama JI, Naiki K, Sugawara K, Nakayama N, Imai Y, Tomiya T, Mochida S. Uchida Y, et al. Among authors: uemura h. PLoS One. 2022 Feb 18;17(2):e0262764. doi: 10.1371/journal.pone.0262764. eCollection 2022. PLoS One. 2022. PMID: 35180213 Free PMC article.
Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral response by sofosbuvir plus velpatasvir.
Uchida Y, Imai Y, Tsuji S, Uemura H, Kouyama JI, Naiki K, Ando S, Sugawara K, Nakao M, Nakayama N, Mizuno S, Tomiya T, Mochida S. Uchida Y, et al. Among authors: uemura h. Hepatol Res. 2023 Sep;53(9):815-828. doi: 10.1111/hepr.13926. Epub 2023 Jun 15. Hepatol Res. 2023. PMID: 37243512
1,395 results